Renaissance Technologies (RenTech)'s PACB Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 2.49 M shares of Pacific Biosciences of California, Inc. (PACB) worth $3.29 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in PACB, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 3.85 M shares. Largest reduction occurred in Q1 2026, reducing 1.36 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Pacific Biosciences of California (PACB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pacific Biosciences of California (PACB) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -1.36 M | Reduce 35.36% | 2.49 M | $1.32 |
| Q4 2025 | +3.85 M | New Buy | 3.85 M | $1.87 |
| Q4 2023 | -326,622 | Sold Out | 0 | $0.00 |
| Q3 2023 | +326,622 | New Buy | 326,622 | $8.35 |
| Q3 2022 | -114,200 | Sold Out | 0 | $0.00 |
| Q2 2022 | -754,500 | Reduce 86.85% | 114,200 | $4.42 |
| Q1 2022 | +868,700 | New Buy | 868,700 | $9.10 |
| Q4 2021 | -273,800 | Sold Out | 0 | $0.00 |
| Q3 2021 | -547,000 | Reduce 66.64% | 273,800 | $25.55 |
| Q2 2021 | +37,300 | Add 4.76% | 820,800 | $34.97 |
| Q1 2021 | +783,500 | New Buy | 783,500 | $33.31 |
| Q1 2018 | -113,900 | Sold Out | 0 | $0.00 |
| Q4 2017 | +113,900 | New Buy | 113,900 | $2.64 |
| Q4 2016 | -374,900 | Sold Out | 0 | $0.00 |
| Q3 2016 | -29,164 | Reduce 7.22% | 374,900 | $8.96 |
| Q2 2016 | -784,636 | Reduce 66.01% | 404,064 | $7.04 |
| Q1 2016 | -397,700 | Reduce 25.07% | 1.19 M | $8.50 |
| Q4 2015 | +1.59 M | New Buy | 1.59 M | $13.13 |
| Q3 2015 | -309,500 | Sold Out | 0 | $0.00 |
| Q2 2015 | +184,300 | Add 147.20% | 309,500 | $5.76 |
| Q1 2015 | -12,772 | Reduce 9.26% | 125,200 | $5.84 |
| Q4 2014 | +137,972 | New Buy | 137,972 | $7.84 |
| Q2 2014 | -105,766 | Sold Out | 0 | $0.00 |
| Q1 2014 | +105,766 | New Buy | 105,766 | $5.35 |
| Q4 2013 | -280,100 | Sold Out | 0 | $0.00 |
| Q3 2013 | +4,100 | Add 1.49% | 280,100 | $5.52 |
| Q2 2013 | +276,000 | Add 0.00% | 276,000 | $2.53 |
Renaissance Technologies (RenTech)'s Pacific Biosciences of California Investment FAQs
Renaissance Technologies (RenTech) first purchased Pacific Biosciences of California, Inc. (PACB) in Q2 2013, acquiring 276,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Pacific Biosciences of California, Inc. (PACB) for 27 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Pacific Biosciences of California, Inc. (PACB) was in Q4 2025, adding 3,850,600 shares worth $7.2 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 2,489,100 shares of Pacific Biosciences of California, Inc. (PACB), valued at approximately $3.29 M.
As of the Q1 2026 filing, Pacific Biosciences of California, Inc. (PACB) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Pacific Biosciences of California, Inc. (PACB) was 3,850,600 shares, as reported at the end of Q4 2025.